Mission Statement

The Asia - Pacific region has the fastest growing rate of peritoneal dialysis (PD) in the world, yet includes diverse socioeconomic and health-care environments. For example, highly developed economies such as Japan, Taiwan, Australia, New Zealand and the city states of Hong Kong and Singapore have well organised and effective healthcare programs, whilst the Indian subcontinent has a less well financed and effective system, but is rapidly evolving and improving.Somewhere between these extremes, there are further gradations with relatively more developed health care economics such as Korea and Brunei at one level, and developing countries such as China, Thailand, Malaysia and Indonesia, at another. There are also cultural and financial dissimilarities even within relatively small geographically regions, meaning that there is a very diverse distribution in provision of renal replacement services across the Asia Pacific region.


There also are synergies with other regions such as countries in Africa (e.g., Algeria, Morocco, Tunisia, Egypt, Kenya, South Africa, Nigeria) and Europe (Turkey and Israel) that share similar problems and have common interests in areas such as PD programs.


APC-ISPD

The idea of an Asia-Pacific Chapter of the International Society for Peritoneal dialysis (APC-ISPD) was put forward in 2000, and this society has now matured into an important and influential group within the ISPD structure. Founded not only to stimulate interaction and exchange of ideas, but also to help those working in less advanced settings to approach the levels of medical competency achieved by those in more advanced areas by provision of education and support.


Cost

Fundamental to the provision of renal replacement therapy is cost, and particularly the comparative economics of providing PD versus haemodialysis (HD). It is argued by many that this is the major barrier for the low PD penetration in some regions. We believe PD compares favorably with HD when full economic costs are considered, particularly when PD fluid is manufactured locally. Factors frequently neglected when making such comparisons include;Travel expenses,frequency of blood tests, erythropoiet in usage, loss of productive man-hours, rehabilitation potential, cross-transmission of viral infection, preservation of residual renal function, costs of water purification and hospitalizations.


Aims

The aim of the Society is to highlight and disseminate good practice and to facilitate practical solutions that help promote greater use of PD in the region. In addition we wish to raise standards of PD therapy provision in the region by achieving a high level of academic output.